Ondine Biomed Regulatory News (OBI)

11 October 2022

Ondine Biomedical Inc.

("Ondine" or the "Company")

Investor Presentation

Ondine Biomedical Inc. (AIM: OBI) is pleased to announce that Dr Nicolas Loebel, President and Chief Technology Officer, will provide a live presentation relating to a business update following its recent interim results[i] via the Investor Meet Company platform on Friday 14 October 2022 at 3:00pm BST.

The presentation is open to all retail and institutional investors. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Ondine Biomedical Inc. via:

https://www.investormeetcompany.com/ondine-biomedical-inc/register-investor

Investors who already follow Ondine Biomedical Inc. on the Investor Meet Company platform will automatically be invited.

Should any institutional investors wish to have a follow on meeting with the Company they should contact the investor relations teams or their usual sales team contact at Singer Capital Markets or RBC Capital Markets.

For more information, please visit: www.ondinebio.com or contact: 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Products include therapies for a variety of medical indications such as nasal disinfection, sinusitis, ventilator-associated pneumonia, burns, and other indications. Ondine's nasal photodisinfection technology is approved in several jurisdictions under the brand name Steriwave™. It has been awarded the CE mark and, in the US, has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA.